Education
About Us
Working with TipRanks
Follow Us
Sandoz Group Ltd Sponsored ADR (SDZNY)
OTHER OTC:SDZNY
SDZNY Stock Chart & Stats
$75.80
$0.55(1.34%)
At close: 4:00 PM EST
$75.80
$0.55(1.34%)
Day’s Range― - ―
52-Week Range$36.26 - $93.65
Previous CloseN/A
Volume11.52K
Average Volume (3M)13.20K
Market Cap
$34.24B
Enterprise Value$37.62B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$5.68B
Price to Earnings (P/E)18.4
Beta0.47
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)1.24
Shares Outstanding440,000,000
10 Day Avg. Volume3,665
30 Day Avg. Volume13,196
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.34
Price to Sales (P/S)3.55
P/FCF Ratio38.74
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit9.05
Enterprise Value/Ebitda25.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biosimilars MomentumBiosimilars reaching ~30% of sales and showing double‑digit growth shifts revenue toward higher‑margin biologics. That improves revenue quality and reduces dependence on commoditized generics. Coupled with the Just‑Evotec acquisition and a Slovenia hub, it strengthens development and manufacturing scale advantages for durable competitive positioning.
Margin ResilienceSandoz's sustained gross margins in the mid/high‑40s and a core EBITDA margin increase to ~21.7% reflect structural cost efficiency and favorable product mix. Stable gross margins provide operating leverage, supporting durable profitability even with volume swings and enabling reinvestment in pipeline and manufacturing to preserve margin over time.
Improved Cash & LeverageA meaningful jump in free cash flow to ~$1.5bn and net debt/EBITDA near ~1.5x materially strengthens financial flexibility. This durable cash generation supports peak biosimilars CapEx (~$1.1bn), integration of acquisitions, and capital discipline without excessive leverage, improving resiliency across cycles (noting reported FX noise).
Bears Say
Price ErosionPersistent low‑to‑mid single‑digit price erosion is a structural pressure in generics markets. Over time this compresses unit revenues and limits margin expansion unless offset by higher‑margin mix or sustained cost reductions. It forces continuous efficiency gains or strategic shift toward biosimilars to maintain long‑run profitability.
Penicillin API DisruptionAggressive API dumping and market distortion in penicillin indicate durable supply‑side volatility for essential antibiotics. Such structural disruptions can depress realized sales value, force price concessions, and create recurring revenue volatility in that portfolio, limiting predictability and raising the need for strategic sourcing or portfolio shifts.
Regulatory / IP RiskComplex patent landscapes, unpredictable regulatory outcomes, and sporadic injunctions create structural timing and access risk for biosimilars. These legal and regulatory uncertainties can materially delay revenue recognition from launches, increase litigation and compliance costs, and extend payback periods on R&D and heavy manufacturing investments.
Sandoz Group Ltd Sponsored ADR News
SDZNY FAQ
What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?
Sandoz Group Ltd Sponsored ADR lowest stock price was $36.26 and its highest was $93.64 in the past 12 months.
What is Sandoz Group Ltd Sponsored ADR’s market cap?
Sandoz Group Ltd Sponsored ADR’s market cap is $34.24B.
When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?
Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 144 days.
How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?
Sandoz Group Ltd Sponsored ADR released its earnings results on Feb 25, 2026. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of N/A by $1.24.
Is Sandoz Group Ltd Sponsored ADR overvalued?
According to Wall Street analysts Sandoz Group Ltd Sponsored ADR’s price is currently Overvalued.
Does Sandoz Group Ltd Sponsored ADR pay dividends?
Sandoz Group Ltd Sponsored ADR pays a Annually dividend of $0.727 which represents an annual dividend yield of 0.98%. See more information on Sandoz Group Ltd Sponsored ADR dividends here
What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?
Sandoz Group Ltd Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?
Sandoz Group Ltd Sponsored ADR has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?
Sandoz Group Ltd Sponsored ADR reported an EPS of $1.24 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 10.536%.
Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in SDZNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sandoz Group Ltd Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
SDZNY Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.01%
12-Months-Change
Fundamentals
Return on Equity
10.09%
Trailing 12-Months
Asset Growth
10.67%
Trailing 12-Months
Company Description
Sandoz Group Ltd Sponsored ADR
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
SDZNY Company Deck
SDZNY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial performance with multiple clear achievements: revenue exceeded $11 billion, biosimilars gained share and drove margin expansion, cash generation and EPS improved materially, and strategic investments (Just-Evotec acquisition and a Slovenian biosimilars hub) position the company for future growth. Notable near-term headwinds include penicillin B2B price disruption, ongoing low- to mid-single-digit price erosion, FX impacts on reported net debt, one-off integration and IT costs, and regulatory/IP uncertainties (especially in the U.S.) that could affect timing and scale of some opportunities. On balance, the highlights (broad-based sales growth, margin expansion, strong cash flow, successful launches, strengthened pipeline and manufacturing investments) outweigh the lowlights, which are significant but largely manageable and either transient or being mitigated through strategic actions.View all SDZNY earnings summariesTechnical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Ownership Overview
―
Insiders
0.19% Mutual Funds
0.05% Other Institutional Investors
99.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---